Zobrazeno 1 - 3
of 3
pro vyhledávání: ''
Autor:
Yuxin Mu, Ziyi Xu, Junling Li, Jinyao Zhang, Puyuan Xing, Xuezhi Hao, Teng Li, Yan Wang, Xingsheng Hu
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Purpose Osimertinib, a third-generation epidermal growth factor receptor tyrosine-kinase inhibitor (EGFR-TKI), has demonstrated substantial clinical benefit in patients with non-small-cell lung cancer (NSCLC) who were resistant to early-generation EG
Autor:
Mitsuyoshi Utsugi, Reiko Sakurai, Noriaki Sunaga, Akira Mogi, Yoshio Tomizawa, Tomohito Kuwako, Tomomi Masuda, T. Ishizuka, Kyoichi Kaira, Atsushi Takise, Yosuke Miura, Ryusei Saito, Kimihiro Shimizu, Kaori Seki, Koichi Minato, Masanobu Yamada, Hisao Imai, Shinichi Ishihara, Takeshi Hisada
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose In patients with epidermal growth factor receptor (EGFR)-mutated, advanced, non-small cell lung cancer (NSCLC), common gefitinib-sensitive EGFR mutations that predict a greater response to therapy include the exon 19 deletion and L858R point
Autor:
Juliusz Pankowski, Monika Pasieka-Lis, Ewa Kalinka-Warzocha, Dariusz M. Kowalski, Janusz Milanowski, Aldona Woźniak, Jacek Jassem, Bożena Jarosz, Joanna Chorostowska-Wynimko, Bartosz Wasąg, Rodryg Ramlau, Marzena Anna Lewandowska, Maciej Krzakowski, Tomasz Powrózek, Justyna Szumiło, Paweł Krawczyk, Rafal Dziadziuszko, Kamila Wojas-Krawczyk, Wojciech Dyszkiewicz, Michal Skronski, Jerzy Kozielski, Ewelina Antoszewska, Janusz Limon, Wojciech Jóźwicki, Aleksandra Szczesna, Paulina Jaguś
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Introduction Testing for the epidermal growth factor receptor (EGFR) gene mutations requires considerable multidisciplinary experience of clinicians (for appropriate patient selection), pathologists (for selection of appropriate cytological or histol